Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

I investigate special situations, pairs, and index rebalancing trades in Korea.

Korea / Special Sits, Pairs, Index Rebalancing

Clepsydra Capital

Investigate special situations, pairs, and index rebalancing trades in Korea.

Event-Driven

<ul>
<li>HLB expects Jiangsu Hengrui to receive another CRL from the FDA, but specifics on CMC issues remain unclear. Due to the lack of clarity, it's advisable to avoid trading HLB.</li>
<li>HLB IR stated they'll apply for KOSPI transfer listing after FDA approval when asked by local media, suggesting it's currently not under consideration.</li>
<li>We should instead consider short-term trading opportunities in HLB Life Science. Anticipate a surge in forfeited shares from Day 1, reminiscent of last year's CJ CGV rights offer event.</li>
</ul>


HLB expects Jiangsu Hengrui to receive another CRL from the FDA, but specifics on CMC issues remain unclear. Due to the lack of clarity, it's advisable to avoid trading HLB.
HLB IR stated they'll apply for KOSPI transfer listing after FDA approval when asked by local media, suggesting it's currently not under consideration.
We should instead consider short-term trading opportunities in HLB Life Science. Anticipate a surge in forfeited shares from Day 1, reminiscent of last year's CJ CGV rights offer event.


What's Still Concerning in the HLB Situation & HLB Life Science's Stock Rights Trading Next Week